Clinical decision on a patient with ALK+ diffuse large B cell lymphoma

Ling Dong, Bin Meng, Xinwei Zhang, Xiuyu Song, Ximei Zhang, Qiongli Zhai, Xia Liu, Yun Hou, Wei Li, Xianhuo Wang, Huaqing Wang, Kai Fu, Huilai Zhang

Research output: Contribution to journalArticlepeer-review

Abstract

Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (DLBCL) is a rare and distinct variant of DLBCL. It is classified as a unique subtype of DLBCL in the 2008 WHO classification of lymphomas. No standard and effective therapeutic regimen is available for ALK+DLBCL because it shows a more aggressive clinical course and frequent relapse. Therefore, a standardized and individualized treatment is needed to benefit more patients diagnosed with ALK+DLBCL through a multiple disciplinary team. This article presents a case of an ALK+DLBCL patient who relapsed after transplantation and was successfully treated with the ALK kinase inhibitor Crizotinib.

Original languageEnglish (US)
Pages (from-to)385-391
Number of pages7
JournalChinese Journal of Clinical Oncology
Volume43
Issue number9
DOIs
StatePublished - 2016

Keywords

  • Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (ALK + DLBCL)
  • Crizotinib
  • Multiple disciplinary team (MDT)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Clinical decision on a patient with ALK+ diffuse large B cell lymphoma'. Together they form a unique fingerprint.

Cite this